Summary:
We compared the incidence and outcome of preemptively treated cytomegalovirus (CMV) infection, lymphocyte recovery and non-CMV infections between two different TCD modalities, one employing CD34+ selection and T-cell add-back (TCAB), preceded by Campath-1H in vivo (CD34+/TCAB group, n=29), and the other using grafts incubated with Campath-1H in vitro (Campath-1H in vitro group, n=32). The probabilities of CMV reactivation and recurrence were 67 and 83.6% in the CD34+/TCAB group and 42.9 and 20% in the Campath-1H group (P=0.07 and 0.02). Donor sero-positivity reduced CMV reactivation in the Campath-1H group, but not in the CD34+/TCAB group. The durations of positive PCR/antigenemia positivity and antiviral therapy were also significantly longer in the CD34+/TCAB group. However, only two patients developed CMV disease in each group. The mean absolute lymphocyte counts (× 109/l) at 30 days (0.27 vs 0.4, P=0.03) and 100 days (0.77 vs 1.4, P=0.01) were significantly lower in the CD34+/TCAB group along with a higher incidence of non-CMV infections in CMV at-risk patients, but not in the CMV low-risk group. These findings suggest that the modality of TCD should be tailored according to the CMV risk status, and CMV sero-positive patients should receive a less extensively T-cell-depleted graft and a CMV sero-positive graft if possible.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971–1979.
Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow recipients. Clin Infect Dis 1999; 28: 618–623.
Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based pre-emptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757–763.
Ljungman P . Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44–57.
Ljungman P, Deliliers GL, Platzbecker U et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388–392.
Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001; 97: 1232–1240.
Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–3922.
Broers AE, van Der Holt R, van Essen JW et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240–2245.
Craddock C, Szydlo RM, Dazzi F et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2000; 112: 228–236.
Kroger N, Zabelina T, Kruger W et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060–1071.
Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488.
Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461–464.
Couriel D, Canosa J, Engler H et al. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18: 347–353.
Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15: 387–393.
Martino R, Rovira M, Carreras E et al. The AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001; 86: 1075–1086.
Hebart H, Brugger W, Grigoleit U et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based pre-emptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183–2185.
Chakrabarti S, Brown J, Guttridge M et al. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T cell addback. Bone Marrow Transplant 2003; 32: 23–30.
Chakrabarti S, MacDonald D, Hale G et al. T cell depletion with Campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109–118.
Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357–4363.
Chakrabarti S, Collingham KE, Fegan CD et al. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001; 28: 759–763.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Hale G . The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137–143.
Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467–480.
Rebello P, Cwynarsky K, Varughese M et al. Pharmacokinetics of Campath-1H in bone marrow transplant patients. Cytotherapy 2002; 3: 261–267.
Chakrabarti S, Mautner V, Osman H et al. Adenovirus infections following allogeneic stem cell transplantation: the incidence and outcome in relation to graft manipulation, immunosuppression and immune recovery. Blood 2002; 100: 1619–1627.
Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72: 1460–1463.
Chakrabarti S, Osman H, Collingham K et al. Polyoma viruria in stem cell transplant recipients T cell depleted with Campath-1H: the incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003; 31: 379–386.
Chakraverty R, Robinson S, Peggs K et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 827–834.
Grob JP, Grundy JE, Prentice HG et al. Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774–776.
Lin TS, Zahrieh D, Weller E et al. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002; 74: 49–54.
Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815–2820.
Reusser P, Einsele H, Lee J et al. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159–1164.
Williamson EC, Millar MR, Steward CG et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560–568.
Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.
Grigoleit GU, Riegler S, Hebart H et al. Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocytes-derived immature dendritic cells. Bone Marrow Transplant 2002; 29 (Suppl.): S32.
Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179–184.
Ljungman P, Brand R, Einsele H et al. Donor CMV serological status influences the outcome after unrelated donor stem cell transplantation; an EBMT Megafile analysis. Bone Marrow Transplant 2002; 29 (Suppl.): S32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chakrabarti, S., Milligan, D., Brown, J. et al. Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens. Bone Marrow Transplant 33, 197–204 (2004). https://doi.org/10.1038/sj.bmt.1704334
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704334
Keywords
This article is cited by
-
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
International Journal of Hematology (2010)
-
Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT
Bone Marrow Transplantation (2009)
-
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival
Bone Marrow Transplantation (2006)
-
Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion
Bone Marrow Transplantation (2005)